Eli Lilly, a global pharmaceutical company, has announced the launch of Copellor®(Ixekizumab) in India for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Copellor®(Ixekizumab) is a humanized IgG4 monoclonal antibody that specifically targets IL-17A, a protein responsible for triggering and maintaining inflammation in psoriasis. The drug has received approval from The Drug Controller General of India (DCGI) and is available in one strength of 80 mg/ml in a single-dose prefilled autoinjector.
According to global studies, psoriasis has a severe impact on the quality of life of patients and is comparable to that of serious diseases such as cancer and heart failure. The availability of Copellor®(Ixekizumab) will provide healthcare providers in India with another treatment option for adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis. Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, said that their entry into the dermatology segment strengthens Lilly’s promise of bringing innovative medicines to India.
However, it is recommended that Copellor®(Ixekizumab) be used only on the advice of a dermatologist or rheumatologist and under medical supervision. The launch of Copellor®(Ixekizumab) reinforces Eli Lilly’s commitment to improving patient outcomes and quality of life through innovative treatments in India. This launch is also a testament to Eli Lilly’s dedication to providing effective treatment options and improving the lives of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis in India.
